Posted by Michael Wonder on 05 Aug 2020
ReViral announces FDA fast track designation granted to sisunatovir for the treatment of serious respiratory syncytial virus infection
4 August 2020 - ReViral today announced that the U.S. FDA has granted fast track designation to sisunatovir for the treatment of patients with serious RSV infection.
Sisunatovir is the company’s most advanced product candidate, with two international multi-centre Phase 2 clinical studies recently initiated in paediatric and high-risk adult patient populations.
